---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-048830"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:30:48.944835+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley

## Summary
- Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.
- Roth Capital Partners added as Sales Agent; B. Riley Securities removed.
- Raymond James & Associates and Roth Capital Partners remain as the two Sales Agents.
- No changes to the $0.001 par value common stock or ATM program terms beyond agent roster.
- Agreement governs at-the-market equity offering program for ChromaDex common stock.

## SEC filing metadata
- accession: 0001628280-24-048830
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/0001628280-24-048830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-048830
- JSON: https://secwatch.observer/filing/0001628280-24-048830.json
- Plain text: https://secwatch.observer/filing/0001628280-24-048830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.